

Supplementary Table S1.1 Changes in HbA1c ranges after 12-month follow-up for dapagliflozin group

HbA1c baseline range	HbA1c follow up range					Total	p-value
	<7.5	7.5-8.4	8.5-9.4	9.5-10.4	10.5-11.4		
7.5-8.4	8	12	1	0	0	21	<0.001
8.5-9.4	4	11	9	1	0	25	
9.5-10.4	0	7	3	0	0	10	
10.5-11.4	2	1	7	4	2	16	
>11.4	2	1	2	1	0	6	
Total	16	32	22	6	2	78	

Supplementary Table S1.2 Mean change in the clinical parameters after 12-month follow-up between the two dapagliflozin groups (sub-analysis)

	N (n=26)	Mean	N (n=52)	Mean	p-value
		Dapa+Met ± 1 or more OHA		Dapa+Met+insulin ± 1 or more OHA	
HbA1c, %	26	-1.15 ± 0.99	52	-1.26 ± 1.34	0.724
Weight, kg	26	-1.22 ± 2.86	52	-1.99 ± 3.55	0.343
BMI, kg/m ²	26	-0.56 ± 1.10	52	-0.77 ± 1.31	0.482
Glucose, mmol/L	23	-2.89 ± 3.20	43	-2.04 ± 2.95	0.284
SBP, mm Hg	26	-0.82 ± 12.22	52	-4.60 ± 11.77	0.191
DBP, mm Hg	26	1.78 ± 8.73	52	-0.57 ± 7.53	0.221
LDL, mmol/L	23	-0.21 ± 0.66	43	-0.05 ± 0.53	0.276
HDL, mmol/L	23	0.02 ± 0.18	44	0.03 ± 0.14	0.74
TG, mmol/L	23	-0.18 ± 0.48	43	-0.27 ± 0.61	0.571
TC, mmol/L	23	-0.27 ± 0.76	44	-0.19 ± 0.47	0.628
Scr, mcmmol/L	26	-0.33 ± 6.89	49	-0.41 ± 8.55	0.968
eGFR, ml/min/1.73m ²	26	0.16 ± 6.68	49	0.49 ± 8.22	0.862
Hct, %	5	1.57 ± 0.75	20	1.07 ± 2.62	0.679
BUN, mmol/L	22	0.35 ± 0.97	43	0.53 ± 1.10	0.525
Na ⁺ , mmol/L	22	1.53 ± 2.19	43	1.36 ± 2.37	0.78
K ⁺ , mmol/L	22	0.02 ± 0.30	43	-0.03 ± 0.34	0.568
Microalbuminuria (mg/L)	2	-34.00 ± 15.56	14	-132.45 ± 179.35	0.464

Dapa: Dapagliflozin; Met: Metformin; OHA: Oral Hypoglycemic Agent; BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; TG: Triglycerides; TC: Total Cholesterol; Scr: Serum Creatinine; eGFR: Estimated Glomerular Filtration Rate; Hct: Hematocrit; BUN: Blood Urea Nitrogen; Na⁺: Sodium; K⁺: Potassium

Supplementary Table S1.3 Adverse events during 12-month follow-up (sub-analysis)

		N (n=78)	Dapa+Met ± 1 or more OHA	Dapa+Met+insulin ± 1 or more OHA	p-value	Male	Female	p-value
Hypoglycemia		26 (33.3)	5 (6.4)	21 (26.9)	0.077			
Hypoglycemia no. of episodes	(1-2)	11 (14.1)	4 (36.4)	7 (63.6)	0.109			
	(3-4)	9 (11.5)	1 (11.1)	8 (88.9)				

	>4	6 (7.7)	0	6 (100.0)				
Hypoglycemia severity	Mild	25 (32.1)	4 (5.1)	21 (26.9)	0.038			
	Moderate	2 (2.6)	1 (1.3)	1 (1.3)	>0.05			
	Severe	0	0	0				
UTI		10 (12.8)	3 (3.8)	7 (9.0)	>0.05	1 (1.3)	9 (11.5)	0.162
Genital infection		14 (17.9)	6 (7.7)	8 (10.2)	0.533	0	14 (17.9)	0.004
UTI and genital infection severity	Mild	18 (23.1)	6 (7.7)	12 (15.4)	>0.05			
	Moderate	0	0	0				
	Severe	1 (1.3)	0	1 (1.3)				
Treatment	yes, needed treatment	9 (11.5)	4 (5.1)	5 (6.4)	0.471			
	Self-treatable	14 (17.9)	4 (5.1)	10 (12.8)	0.764			
Polyuria		8 (10.2)	5 (6.4)	3 (3.8)	0.109	1 (1.3)	7 (8.9)	0.423
Dysuria		10 (12.8)	2 (2.6)	8 (10.2)	0.482	2 (20.0)	8 (80.0)	0.715
Microalbuminuria during follow-up		7 (9.0)	1 (1.3)	6 (7.7)	0.414			
Dapa: Dapagliflozin; Met: Metformin; OHA: Oral Hypoglycemic Agent; UTI: Urinary Tract Infection								